GlassScriptPhysician profile
Sara Alysse Mills
NPI 1336373794
$663.41
in general payments reported to CMS, 2019-2025
13 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $156.62 | 2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $124.81 | 2025 | |
| Lilly USA, LLC | $116.93 | 2025 | Kisunla, Zepbound, Mounjaro |
| Abbott Laboratories | $44.11 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $41.04 | 2025 | |
| Glaxosmithkline, LLC. | $29.22 | 2025 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $28.27 | 2025 | Gardasil 9, Capvaxive |
| Sumitomo Pharma America, INC. | $26.01 | 2025 | Gemtesa |
| Astellas Pharma US INC | $24.63 | 2025 | Veozah |
| Dexcom, INC. | $23.74 | 2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $17.69 | 2025 | Gvoke Hypopen |
| Baxter Healthcare | $16.75 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $13.59 | 2025 | Intellis Adaptivestim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Mills listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.